Site Editor

David S. Ettinger, MD, FACP, FCCP


ESMO 2022: Interim Results From DESTINY-Lung02 Trial of T-DXd in NSCLC

By: Kayci Reyer
Posted: Friday, September 23, 2022

According to interim results from the DESTINY-Lung02 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA55), treatment with fam-trastuzumab deruxteca-nxki (T-DXd) may result in clinically significant activity in some patients with metastatic non–small cell lung cancer (NSCLC). Koichi Goto, MD, PhD, of the National Cancer Center Hospital East, Tokyo, and colleagues evaluated the outcomes associated with the administration of this HER2-targeting antibody-drug conjugate to patients with previously treated, HER2-mutant metastatic disease.

The phase II trial included 80 patients in the prespecified early cohort who received treatment at least 4.5 months prior to the data cutoff of March 2022 and 151 patients in the safety analysis set. In the prespecified early cohort, patients were randomly assigned 2:1 to receive either 5.4 mg/kg (n = 52) or 6.4 mg/kg (n = 28) of T-DXd. The safety analysis set included 101 patients who received 5.4 mg/kg, and 50 patients who received 6.4 mg/kg of the combination treatment. Median follow-up was 5.6/5.4 months in the early cohort and 3.8/3.9 months in the safety analysis subset for patients who received 5.4 mg/kg or 6.4 mg/kg of T-DXd, respectively.

The confirmed objective response rate in the early cohort was 53.8% in the lower-dose group and 42.9% in the higher-dose group. In the safety analysis set, adjudicated treatment-related interstitial lung disease of any grade occurred in 5.8% of patients in the lower-dose group and 14.0% of patients in the higher-dose group. Overall, treatment-emergent adverse events were more common in the higher-dose groups.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.